Literature DB >> 26845106

Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.

Glen R Monroe1,2, Gerardus W Frederix3, Sanne M C Savelberg1,2, Tamar I de Vries1, Karen J Duran1,2, Jasper J van der Smagt1, Paulien A Terhal1, Peter M van Hasselt4, Hester Y Kroes1, Nanda M Verhoeven-Duif1,2, Isaäc J Nijman1,2, Ellen C Carbo1,2, Koen L van Gassen1, Nine V Knoers1,2, Anke M Hövels3, Mieke M van Haelst1, Gepke Visser4, Gijs van Haaften1,2.   

Abstract

PURPOSE: This study investigated whole-exome sequencing (WES) yield in a subset of intellectually disabled patients referred to our clinical diagnostic center and calculated the total costs of these patients' diagnostic trajectory in order to evaluate early WES implementation.
METHODS: We compared 17 patients' trio-WES yield with the retrospective costs of diagnostic procedures by comprehensively examining patient records and collecting resource use information for each patient, beginning with patient admittance and concluding with WES initiation. We calculated cost savings using scenario analyses to evaluate the costs replaced by WES when used as a first diagnostic tool.
RESULTS: WES resulted in diagnostically useful outcomes in 29.4% of patients. The entire traditional diagnostic trajectory average cost was $16,409 per patient, substantially higher than the $3,972 trio-WES cost. WES resulted in average cost savings of $3,547 for genetic and metabolic investigations in diagnosed patients and $1,727 for genetic investigations in undiagnosed patients.
CONCLUSION: The increased causal variant detection yield by WES and the relatively high costs of the entire traditional diagnostic trajectory suggest that early implementation of WES is a relevant and cost-efficient option in patient diagnostics. This information is crucial for centers considering implementation of WES and serves as input for future value-based research into diagnostics.Genet Med 18 9, 949-956.

Entities:  

Mesh:

Year:  2016        PMID: 26845106     DOI: 10.1038/gim.2015.200

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  36 in total

1.  Distribution and intensity of constraint in mammalian genomic sequence.

Authors:  Gregory M Cooper; Eric A Stone; George Asimenos; Eric D Green; Serafim Batzoglou; Arend Sidow
Journal:  Genome Res       Date:  2005-06-17       Impact factor: 9.043

2.  Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study.

Authors:  Anita Rauch; Dagmar Wieczorek; Elisabeth Graf; Thomas Wieland; Sabine Endele; Thomas Schwarzmayr; Beate Albrecht; Deborah Bartholdi; Jasmin Beygo; Nataliya Di Donato; Andreas Dufke; Kirsten Cremer; Maja Hempel; Denise Horn; Juliane Hoyer; Pascal Joset; Albrecht Röpke; Ute Moog; Angelika Riess; Christian T Thiel; Andreas Tzschach; Antje Wiesener; Eva Wohlleber; Christiane Zweier; Arif B Ekici; Alexander M Zink; Andreas Rump; Christa Meisinger; Harald Grallert; Heinrich Sticht; Annette Schenck; Hartmut Engels; Gudrun Rappold; Evelin Schröck; Peter Wieacker; Olaf Riess; Thomas Meitinger; André Reis; Tim M Strom
Journal:  Lancet       Date:  2012-09-27       Impact factor: 79.321

3.  Clinical whole exome sequencing in child neurology practice.

Authors:  Siddharth Srivastava; Julie S Cohen; Hilary Vernon; Kristin Barañano; Rebecca McClellan; Leila Jamal; SakkuBai Naidu; Ali Fatemi
Journal:  Ann Neurol       Date:  2014-08-30       Impact factor: 10.422

4.  Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders.

Authors:  Sarah E Soden; Carol J Saunders; Laurel K Willig; Emily G Farrow; Laurie D Smith; Josh E Petrikin; Jean-Baptiste LePichon; Neil A Miller; Isabelle Thiffault; Darrell L Dinwiddie; Greyson Twist; Aaron Noll; Bryce A Heese; Lee Zellmer; Andrea M Atherton; Ahmed T Abdelmoity; Nicole Safina; Sarah S Nyp; Britton Zuccarelli; Ingrid A Larson; Ann Modrcin; Suzanne Herd; Mitchell Creed; Zhaohui Ye; Xuan Yuan; Robert A Brodsky; Stephen F Kingsmore
Journal:  Sci Transl Med       Date:  2014-12-03       Impact factor: 17.956

5.  De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause of intellectual disability: expanding the mutational and clinical spectrum.

Authors:  Alma Kuechler; Marjolein H Willemsen; Beate Albrecht; Carlos A Bacino; Dennis W Bartholomew; Hans van Bokhoven; Marie Jose H van den Boogaard; Nuria Bramswig; Christian Büttner; Kirsten Cremer; Johanna Christina Czeschik; Hartmut Engels; Koen van Gassen; Elisabeth Graf; Mieke van Haelst; Weimin He; Jacob S Hogue; Marlies Kempers; David Koolen; Glen Monroe; Sonja de Munnik; Matthew Pastore; André Reis; Miriam S Reuter; David H Tegay; Joris Veltman; Gepke Visser; Peter van Hasselt; Eric E J Smeets; Lisenka Vissers; Thomas Wieland; Willemijn Wissink; Helger Yntema; Alexander Michael Zink; Tim M Strom; Hermann-Josef Lüdecke; Tjitske Kleefstra; Dagmar Wieczorek
Journal:  Hum Genet       Date:  2014-10-19       Impact factor: 4.132

6.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.

Authors:  Helen V Firth; Shola M Richards; A Paul Bevan; Stephen Clayton; Manuel Corpas; Diana Rajan; Steven Van Vooren; Yves Moreau; Roger M Pettett; Nigel P Carter
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

7.  Array analysis and karyotyping: workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands.

Authors:  Ron Hochstenbach; Ellen van Binsbergen; John Engelen; Aggie Nieuwint; Abeltje Polstra; Pino Poddighe; Claudia Ruivenkamp; Birgit Sikkema-Raddatz; Dominique Smeets; Martin Poot
Journal:  Eur J Med Genet       Date:  2009-04-09       Impact factor: 2.708

8.  Clinical whole-exome sequencing: are we there yet?

Authors:  Paldeep Singh Atwal; Marie-Louise Brennan; Rachel Cox; Michael Niaki; Julia Platt; Margaret Homeyer; Andrea Kwan; Sylvie Parkin; Susan Schelley; Leah Slattery; Yael Wilnai; Jonathan Adam Bernstein; Gregory M Enns; Louanne Hudgins
Journal:  Genet Med       Date:  2014-02-13       Impact factor: 8.822

9.  The impact of chromosomal microarray on clinical management: a retrospective analysis.

Authors:  Lindsay B Henderson; Carolyn D Applegate; Elizabeth Wohler; Molly B Sheridan; Julie Hoover-Fong; Denise A S Batista
Journal:  Genet Med       Date:  2014-03-13       Impact factor: 8.822

10.  The usefulness of whole-exome sequencing in routine clinical practice.

Authors:  Alejandro Iglesias; Kwame Anyane-Yeboa; Julia Wynn; Ashley Wilson; Megan Truitt Cho; Edwin Guzman; Rebecca Sisson; Claire Egan; Wendy K Chung
Journal:  Genet Med       Date:  2014-06-05       Impact factor: 8.822

View more
  54 in total

1.  Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield.

Authors:  S Anazi; S Maddirevula; E Faqeih; H Alsedairy; F Alzahrani; H E Shamseldin; N Patel; M Hashem; N Ibrahim; F Abdulwahab; N Ewida; H S Alsaif; H Al Sharif; W Alamoudi; A Kentab; F A Bashiri; M Alnaser; A H AlWadei; M Alfadhel; W Eyaid; A Hashem; A Al Asmari; M M Saleh; A AlSaman; K A Alhasan; M Alsughayir; M Al Shammari; A Mahmoud; Z N Al-Hassnan; M Al-Husain; R Osama Khalil; N Abd El Meguid; A Masri; R Ali; T Ben-Omran; P El Fishway; A Hashish; A Ercan Sencicek; M State; A M Alazami; M A Salih; N Altassan; S T Arold; M Abouelhoda; S M Wakil; D Monies; R Shaheen; F S Alkuraya
Journal:  Mol Psychiatry       Date:  2016-07-19       Impact factor: 15.992

2.  Whole-exome sequencing in intellectual disability; cost before and after a diagnosis.

Authors:  Terry Vrijenhoek; Eline M Middelburg; Glen R Monroe; Koen L I van Gassen; Joost W Geenen; Anke M Hövels; Nine V Knoers; Hans Kristian Ploos van Amstel; Gerardus W J Frederix
Journal:  Eur J Hum Genet       Date:  2018-06-29       Impact factor: 4.246

3.  Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting.

Authors:  I Borget; J Bonastre; Arnaud Bayle; N Droin; B Besse; Z Zou; Y Boursin; S Rissel; E Solary; L Lacroix; E Rouleau
Journal:  Eur J Health Econ       Date:  2021-03-25

4.  Economic evaluation of genomic sequencing in the paediatric population: a critical review.

Authors:  Khurshid Alam; Deborah Schofield
Journal:  Eur J Hum Genet       Date:  2018-05-24       Impact factor: 4.246

5.  High Rates of Genetic Diagnosis in Psychiatric Patients with and without Neurodevelopmental Disorders: Toward Improved Genetic Diagnosis in Psychiatric Populations.

Authors:  Joyce So; Venuja Sriretnakumar; Jessica Suddaby; Brianna Barsanti-Innes; Hanna Faghfoury; Timothy Gofine
Journal:  Can J Psychiatry       Date:  2020-06-04       Impact factor: 4.356

6.  Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions.

Authors:  Tiong Yang Tan; Oliver James Dillon; Zornitza Stark; Deborah Schofield; Khurshid Alam; Rupendra Shrestha; Belinda Chong; Dean Phelan; Gemma R Brett; Emma Creed; Anna Jarmolowicz; Patrick Yap; Maie Walsh; Lilian Downie; David J Amor; Ravi Savarirayan; George McGillivray; Alison Yeung; Heidi Peters; Susan J Robertson; Aaron J Robinson; Ivan Macciocca; Simon Sadedin; Katrina Bell; Alicia Oshlack; Peter Georgeson; Natalie Thorne; Clara Gaff; Susan M White
Journal:  JAMA Pediatr       Date:  2017-09-01       Impact factor: 16.193

7.  Potential Role of Genomic Sequencing in the Early Diagnosis of Treatable Genetic Conditions.

Authors:  Hengameh Zahed; Teresa N Sparks; Ben Li; Adnan Alsadah; Joseph T C Shieh
Journal:  J Pediatr       Date:  2017-10       Impact factor: 4.406

Review 8.  A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders.

Authors:  Patrick Fahr; James Buchanan; Sarah Wordsworth
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

Review 9.  Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.

Authors:  Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Value Health       Date:  2020-03-26       Impact factor: 5.725

10.  A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy.

Authors:  Katherine B Howell; Stefanie Eggers; Kim Dalziel; Jessica Riseley; Simone Mandelstam; Candace T Myers; Jacinta M McMahon; Amy Schneider; Gemma L Carvill; Heather C Mefford; Ingrid E Scheffer; A Simon Harvey
Journal:  Epilepsia       Date:  2018-05-11       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.